Researchers found that, in this real-world clinical setting, patients with PsA who had a shorter disease duration achieved better results after treatment with adalimumab than did patients with a longer disease duration. This finding adds support to the idea that shorter symptom duration and earlier treatment with adalimumab could lead to a more favorable outcome in patients with PsA. Researchers did note, however, that further studies are needed to confirm these results.
thumbnail courtesy of centerforbiosimilars.com
You can find more psoriasis and psoriatic arthritis news on our news page.
Additional reading: Lifestyle Changes to Manage Psoriasis – These Improvements Work!